FY26 is a potent Os(II) anticancer drug candidate, exerts its activity by generating reactive oxygen species and disrupting the redox balance in cancer cells Coadministration of FY26 and nontoxic doses of L-BSO allows the potentiation of its anticancer activity, and most remarkably, it improves the selectivity for cancer cells versus normal fibroblasts. FY26 is 49 times more potent than the clinically used treatment Cisplatin. FY26 is able to shut down a cancer cell by exploiting weaknesses inherent in their energy generation.
MedKoo Cat#: 406767
Name: FY26
CAS#: 1255143-82-8
Chemical Formula: C23H28F6IN4OsP
Exact Mass:
Molecular Weight: 822.60
Elemental Analysis: C, 33.58; H, 3.43; F, 13.86; I, 15.43; N, 6.81; Os, 23.13; P, 3.77
The following data is based on the product molecular weight 822.60 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
